Among the thirteen types of water channel proteins, aquaporins (AQPs), which play various essential roles in human physiology, AQP4 is richly expressed in cells of the central nervous system and implicated in pathological conditions such as brain edema. Therefore, researchers have been looking for ways to inhibit AQP4's water-conducting function. Many small molecules have been investigated for their interactions with the residues that form the AQP4 channel entry vestibule on the extracellular side and their interruption of waters entering into the conducting pore. Conducting all-atom simulations on the basis of CHARMM 36 force field, we study one such inhibitor, 5-acetamido-1,3,4-thiadiazole-2-sulfonamide (AZM), to achieve quantitative agreement between the computed and the experimentally measured values of AZM-AQP4 binding affinity. Using the same method, we examine the possibility of plugging up the AQP4 channel around the Asn-Pro-Ala motifs located near the channel center because a small molecule bound there would totally occlude water conduction through AQP4. We compute the binding affinities of 1,2-ethanediol (EDO) and1,3-propanediol (PDO) inside the AQP4 conducting pore and identify the specificities of the interactions. The EDO-AQP4 interaction is weak with a dissociation constant of 80 mM. The PDO-AQP4 interaction is rather strong with a dissociation constant of 328 µM, which indicates that PDO is an efficacious AQP4 inhibitor with sufficiently high potency. Considering the fact that PDO is classified by the US Food and Drug Administration as generally safe, we predict that 1,3-propanediol could be an effective drug for brain edema and other AQP4-correlated neurological conditions.
Introduction
The family of water channel proteins (aquaporins, AQPs) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , consists of aquaporins that conduct water, but not glycerol, and aquaglyceroporins that conduct, in addition to water, glycerol and some other polar solutes. They are present in all living systems, constituting the cell's "plumbing system". In humans, 13 AQPs (AQP0-AQP12), expressed in various cells from head to toe, govern a wide spectrum of physiological functions with broad clinical importance [15, [17] [18] [19] [20] [21] [22] [23] [24] [25] . In particular, AQP4 water channels are an essential component in a number of physiological processes including water movement into and out of the brain, neuro-excitation, as well as astrocyte migration toward injury sites, all of which are important functions in the central nervous system (CNS) [15] . These key roles of AQP4 suggest that inhibitors of this particular water channel could potentially treat (cytotoxic) brain edema by reducing intracranial pressure and water content, epilepsy by increasing the seizure threshold, and CNS injuries (e.g. trauma or stroke) by accelerating neuronal regeneration via reducing the formation of glial scars, respectively [26] [27] [28] [29] [30] [31] [32] [33] [34] . As such, AQP4 is an appealing drug target and the search for its inhibitors is being actively pursued by medical scientists [8, 15, [35] [36] [37] [38] . However, finding an efficacious and potent AQP inhibitor has proven to be challenging [15] . While virtual screening seems to be a good method due to the widely available structural information for AQP, identifying bona fide inhibitors via computational studies has yet to bear fruit. The virtually identified binding of small molecules does not necessarily translate to channel blocking activity; this is particularly true in the case of AQPs due to their small size and narrow aqueous channel. For example, via virtual docking and oocyte functional assays, some of the epilepsy drugs were identified to bind strongly at the entry vestibule of the channel and inhibit AQP4 water conduction at low µM half maximal inhibitory concentrations (IC 50 s) [36] but structural experiments and proteoliposome assays of AQP4 in the presence of mM amounts of these drugs showed otherwise [8] . The lack of crystal structures of AQP4-drug complexes in conjunction with the disagreement about IC 50 s indeed highlights the inaccuracy in binding affinity estimations inherent in the current virtual screening techniques and the need for accurate computation of binding affinities that still takes too long, even on today's high performance supercomputers.
In this paper, we employ our newly developed hybrid steered molecular dynamics (hSMD) method [39, 40] , which is fast (somewhat brute force) and accurate, to investigate one of the epilepsy drugs and two other small molecules shown in Figure 1 by conducting all-atom simulations (model systems illustrated in Figure 2 ) on the basis of CHARMM 36 force field [41, 42] . On 5-acetamido-1,3,4-thiadiazole-2-sulfonamide (AZM), an epilepsy drug tested on AQP4 inhibition [8, 36] , we achieve quantitative agreement between the computed and the experimentally measured [8] values of AZM-AQP4 binding affinity. Using the same method, we examine the possibility of plugging up the AQP4 channel around the NPA motifs located near the channel center because a small molecule bound there would totally occlude water conduction through AQP4. We compute the binding affinities of 1,2-ethanediol (EDO) and 1,3-propanediol (PDO) inside the AQP4 conducting pore and identify the specificities of the interactions. The toxic EDO binds inside the AQP4 channel with a rather weak affinity (dissociation constant 80 mM). The nontoxic PDO-AQP4 interaction is rather strong with a dissociation constant of 328 µM, which leads us to predict that PDO is an efficacious AQP4 inhibitor with sufficiently high potency.
Results
Binding AZM to the AQP4 channel entry vestibule AZM has low solubility in water (4.4 mM at 30°C) [43] . Oocyte functional assay studies suggested high potency of AQP4 inhibition by AZM with a half maximal inhibitory concentration (IC 50 ) in the submicromolar range [36, 37] . However, AZM was not found bound to the protein in experiments of cocrystallizing AQP4 with 5 mM of AZM and the IC 50 measured in proteoliposome experiments was approximately 3 mM [8] . Our all-atom model study shows that AZM does bind to AQP4 in the channel entry vestibule with the sulfonamide group pointing away from the channel (Figure 3 ) but in a pose essentially opposite to what was found in the virtual docking studies which had the sulfonamide group plugging into the channel entry [36, 37] . We conducted a 50 ns MD run for each of the two poses and found that AZM in the latter pose fluctuates away from the protein by itself without being pulled. The pose illustrated in Figure 3 was found to be stable. The end state of the 50 ns run was chosen to be the one initial state for SMD runs of pulling AZM from the bound state to the dissociated state in the extracellular bulk. The fluctuations of the center of mass of AZM in this bound state (the last 10 ns, shown in SI, Figure  S1 ) were used to compute the partial partition in Equation (7). The numerical results are:
(
The PMF along the pulling path was computed from the work curves (shown in SI, Figure S2 ) using the Brownian dynamics fluctuationdissipation theorem [44] . The PMF curve is shown in Figure 3 from which we obtained the PMF difference 0,
Plugging the values of equations (1) and (2) into Equation (7) and then into Equation (6), we obtained the dissociation constant of AZM as 1.8 mM, which is slightly lower than the experimentally measured IC 50 at 3 mM [8] . Considering the fact that AZM fluctuates at the channel entry and thus does not totally plug up the water channel, the IC 50 value should be higher than the dissociation constant. This nearly perfect agreement between our all-atom computation and the proteoliposome functional assay experiments [8] validates our hSMD method that was also validated in other protein-ligand complexes [39] .
Binding PDO inside the AQP4 channel
PDO is a linear chain of three hydrocarbon groups terminated with a hydroxyl on each end ( Figure 1 ). The fluctuations of PDO are nonGaussian along the channel axis (z-axis). On the xy-plane perpendicular to the channel axis, the fluctuations can still be well approximated as Gaussian (shown in SI, Figure S3 ). Therefore, we conducted SMD runs of pulling the z-coordinate of PDO's center of mass while allowing the xy-coordinates to fluctuate inside the AQP4 channel between z= −7.33Å and z= 8.67Å ( Figure 4 ). We chose z= −7.33Å as the interface separating the single-file channel region (z>−7.33Å) from the nonsingle-file channel orifice to the cytoplasmic bulk region. On the xyplane of z= −7.33Å, we recorded the fluctuations of PDO for 10 ns (shown in SI, Figure S3 ). We chose the end state of the 10 ns trajectory as the one initial state from which we conducted SMD runs of pulling PDO along a straight line from z= −7.33Å to the cytoplasmic bulk z< = −15.33Å disallowing xy-fluctuations ( Figure 4 ). From the fluctuations on the interface, we obtained
From the work curves (shown in SI, Figure S4 ), we obtained the 1D PMF along the pulling path through part of the AQP4 channel and the 3D PMF from z= −7.33Å to the cytoplasmic bulk (shown in Figure  4 ). From the PMF curves, after integrating the 1D PMF in the channel region, we obtained
Plugging the numerical results in equations (3) and (4) into equation (11) and then into equation (6), we obtained the dissociation constant of PDO as D k = 328 µM.
PDO vs EDO
In a procedure parallel to the above, we computed the dissociation constant of the highly toxic EDO as 80 mM, which is close to its lethal dosage. This rules out the medical use of EDO as an AQP4 inhibitor. However, it is interesting to note that the nontoxic PDO binds to AQP4 stronger than EDO by a factor of 244. This huge difference stems from the fact that a PDO molecule in a bulk of water outside the AQP4 channel disrupts, on average, 3.8 more water-water hydrogen bonds than an EDO molecule. Additionally, PDO has one more hydrocarbon group than EDO and thus has a stronger vdW interaction with the AQP4 channel.
Discussion

Efficacy of PDO as an AQP4 inhibitor
Illustrated in Figure 5 are the geometric characteristics of the AQP4 water channel. The water pore has a diameter ranging from 1.5 Å to 4.2 Å and thus allows only single-file lining of waters throughout the channel. No two waters can occupy the same z-coordinate inside the channel. However, near the NPA motifs (between z= 0Å and z= 5Å), the pore is wide enough to host a PDO molecule ( Figure 5 , top right panel). Pulling PDO away from this site either way, to the cytoplasmic or the extracellular side, actually causes distortions to the pore-lining side chains of AQP4 because the channel is narrower on both sides of the binding site. When a PDO molecule binds there, it totally occludes the channel from water conduction. And its fluctuations inside the channel will not give space for water to squeeze by. (Another illustration is given in Figure 6 . Therefore, we conclude that PDO is an efficacious inhibitor of AQP4 water conduction.
Potency of PDO as an AQP4 inhibitor
Since a PDO bound to AQP4 totally occludes the water channel, the potency of PDO should be equal to the dissociation constant, IC 50 = k D = 328 µM. Considering that our PMF estimation has an error of ±1.2 kcal/mol, the IC 50 of PDO should be less than 2.4 mM which indicates that PDO as an AQP4 inhibitor has sufficiently high potency. This is particularly true in light of the knowledge that PDO is nontoxic.
Interactions responsible for binding
In the bound state inside the AQP4 channel, PDO displaces two or three waters out of their places, which can be seen by comparing the top and the bottom panels of Figure 6 . The three displaced waters, if not displaced, would form seven hydrogen bonds with the channel residues (three bonds) and with waters (four). In their place, PDO forms one or two hydrogen bonds with the channel residues and two hydrogen bonds with two waters by its two hydroxyl groups. See Figure  6 (top panel) for a snap shot of PDO hydrogen-bonded to His 95 and Asn 97. Altogether, PDO in the bound state disrupts four hydrogen bonds on the average. In the dissociated state, when it is away from the protein, PDO forms four hydrogen bonds with waters. In terms of the hydrogen bonds PDO can form, there is no significant difference between its bound state and its dissociated state. However, in the dissociated state, PDO displaces four waters and disrupts 10 hydrogen bonds if we consider that each water forms 3.5 hydrogen bonds with other waters on the average. Therefore, the system of PDO-proteinwaters has six more hydrogen bonds with PDO in the bound state than in the dissociated state. Additionally, the van der Waals interaction between PDO and the protein is also favorable for PDO to reside at the binding site (Figure 4 , top panel) because it sterically fits in the channel near the NPA motifs. The van der Waals attraction between PDO and AQP4 and the hydrophobic effect (breaking more hydrogen bonds in the aqueous bulk than inside the protein) together are significantly stronger than the cost in conformational energies (SI, Figures S5 and  S6 ). They are also much greater than the term of entropy loss due to binding (estimated in SI to be 4.4 kcal/mol). Therefore, we conclude that the van der Waals and the hydrophobic interactions are the relevant forces in the PDO-AQP4 system. The overall free energy of binding PDO inside AQP4 is approximately
Considering that the binding site of PDO is near the NPA motifs which are conserved across most aquaporins (human or other forms of life), we are tempted to speculate that PDO possibly binds inside other AQP channels as well. In Figure 7 , we show the pore radii of The pore radii of the human AQPs obtained from the PDB coordinates (PDB code: 1H6I, 4CSK, 1FQY, 4NEF, 3GD8, and 3D9S) using the HOLE program [59] . The ar/R selectivity filter and the NPA motifs are marked by SF and NPA bars respectively. human aquaporins whose coordinates are available from the PDB. The similarities between AQPs 2, 4, and 5 suggest that PDO may inhibit these three human aquaporins. However, we should not speculate that PDO would not inhibit AQP1 on the basis of the dissimilarities between AQPs 1 and 4 because the resolution is not sufficiently high for any of the three structures of AQP1. For any one of the aquaporins, we need to conduct detailed computations (currently underway) similar to this current work on AQP4.
Possible medical use of 1,3-propanediol
A number of toxicity studies on PDO have been done to determine the potential harm that PDO may pose to humans. Under the toxicological profile for PDO in the Federal Register (June 12, 2013) [45], a 14-day inhalation toxicity study, a 90-day oral toxicity study, and a developmental toxicity study showed no evidence of any clinical signs of systemic toxicity at the limit dose of PDO. The mutagenic potential of PDO was also evaluated in both in vitro and in vivo experiments, and the results indicate that PDO is not considered mutagenic. Furthermore, the results from these studies indicate that there is no concern for the carcinogenicity of PDO or for the immunotoxicity or neurotoxicity of PDO. As such, the Environmental Protection Agency has concluded that there is a reasonable certainty that aggregate exposure to PDO presents no harm to the general population, including infants and children. The reported no-observed-adverse-effect-levels (NOAELs) are, respectively, 1.8 mg/L in the 14-day inhalation toxicity study; 1,000 mg/kg bw/day in the 90-day oral toxicity study; and 1,000 mg/kg bw/ day in the developmental toxicity study. It is good to point out, however, that there has been one report of human death supposedly involving PDO in the cause of death in 2008 [47] : Two containers of antifreeze were found close to the decedent's body, and via gas chromatography-flame-ionization detection, the concentration of PDO in the decedent's body fluid was found to be 445 mg/dL (i.e. 58.5 mM).
Considering all the afore-stated data and our result that the IC 50 of AQP4 inhibition by PDO is most probably around 328 µM and less than 2.4 mM, which is far less than the NOAELs, it should be safe to use 1,3-propanediol as a drug for brain edema and other AQP-correlated pathological conditions.
Conclusions
Using CHARMM 36 all-atom force fields on the basis of the rigorous PMF formalism, we conducted hSMD simulations to compute the binding affinities of three AQP4 inhibitors: (1) AZM, an epilepsy drug, that binds to the entry vestibule of AQP4 channel and thus prevents waters from entering into the channel; (2) EDO, a toxic compound, that binds inside the channel and thus totally occludes it; and (3) PDO, a nontoxic food additive, that also binds inside the water-conducting pore and totally occludes water conduction. Our computed AZM-AQP4 dissociation constant agrees closely with the in vitro experimental measurement, which along with other tests on ligand-protein complexes shows the validity of our approach and the accuracy of the force field parameters. The weak binding affinity of EDO in conjunction with its toxicity precludes its medical use as an AQP4 inhibitor. In contrast, the reasonably strong affinity of the nontoxic PDO makes it a valid drug candidate. It is worth noting again that the location of the PDO bound state inside the single-file channel of AQP4 renders PDO's efficacy so that the IC 50 is simply equal to the dissociation constant k D . The computed dissociation constant of 328 µM indicates its potency as an AQP4 inhibitor. Taking into account the error bars of the computation, we have 44 µM< k D < 2.4 mM (in accordance with the binding free energy 0 G ∆ = -4.8 ± 1.2 kcal/mol). Therefore, we conclude with high confidence that 1,3-propanediol is an efficacious and potent AQP4 inhibitor, which could be a drug needed for neurotoxic brain edema and other AQP-correlated pathological conditions.
Methods
Parameters and procedures
We used the all-atom force field CHARMM36 [41,42] to represent all interactions. The van der Waals (vdW) cut-off distance was 10 Å with a switching distance of 9 Å. The electrostatic interactions were computed through the Particle-Mesh Ewald (PME) method, and periodic boundary conditions were applied in every direction. The temperature was kept at 298 K and the pressure at 1.0 bar. The timestep was 1.0 fs for the short range interactions and 2.0 fs for the long range interactions, and the Langevin damping coefficient was 5.0 ps -1 . We used NAMD [48] to perform the simulations, and VMD [49] to set up simulation systems, analyze simulation results, and render molecular graphics.
We took the high-resolution crystal structure of AQP4 (PDB code: 3GD8) [8] , embedded the tetramer in a 120 × 120 Å 2 patch of POPE bilayer, added a 30 Å-thick layer of waters to each side of the membrane patch, and salinated the system to an NaCl concentration of 150 mM. In this way, we obtained a pure AQP4 tetramer-membrane system consisting of 150,951 atoms without any ligands that can bind to AQP4. After the initial optimization and 50 ns equilibrium molecular dynamics (MD) run, the system settles down to dimensions of 115.3×112.6×110. 6 Å 3 . This all-atom model system is similar to typical MD studies of AQPs in the current literature [50] [51] [52] [53] [54] [55] pioneered in Ref. 4 . In all MD production runs, we fixed the alpha carbons on the helices that are within the ±10 Å range from the central plane of the membrane to fully respect the crystal structure. Figure 1(A) illustrates the equilibrated system with one PDO in each AQP4 monomer.
Into the entry vestibule of an AQP4 monomer, we placed a 5-acetamido-1,3,4-thiadiazole-2-sulfonamide (AZM) molecule and deleted the waters occupying the site. We conducted a 10 ns MD run for AZM and waters to settle down followed by a 10 ns MD run to sample the fluctuations of AZM at the binding site. The equilibrated AZM-AQP4 structure is illustrated in Figure 1(B) . From the bound state ensemble, we chose one state and conducted SMD runs of pulling AZM from the binding site to the extracellular bulk to compute the potential of mean force (PMF) along the unbinding path. We combined the PMF difference and the fluctuations to compute the binding affinity. In this case, we chose the center of mass of the thiadiazole ring as the pulling center ( Figure 2) . In hSMD runs for binding affinity computation, we used one AZM-AQP4 monomer complex in a 150 mM NaCl saline box of 80×80×109.7 Å 3 without the lipid bilayer. This reduction in system size speeds up simulations considerably but does not introduce additional errors because all the molecules reduced are beyond the cutoff distance from the ligand; the ligand is not charged; and the alpha J Syst Integr Neurosci, 2016 doi: 10.15761/JSIN.1000117 carbons on the central parts of the helices are fixed as in the case of the full tetramer-membrane system.
Into the binding site near the NPA motifs of each AQP4 monomer, we placed an EDO/PDO molecule and deleted waters at or near the site to obtain the EDO/PDO-AQP4-membrane systems. After initial optimization and equilibration, we ran a 10 ns equilibrium MD run to sample EDO/PDO fluctuations. The equilibrated PDO-AQP4 complex is shown in Figure 1(C) . Then we chose one state of the bound state ensemble and conducted SMD runs to compute the PMF along the path of pulling EDO/PDO from the channel to the cytoplasmic bulk and along the path of pulling EDO/PDO through the part of the channel around the NPA motifs. We combined the fluctuations and the PMF differences to compute the binding affinity. In this case we chose the center of mass of the entire ligand molecule as the pulling center (shown in Figure 2 ). In hSMD runs for binding affinity computation, we used one EDO/PDO-AQP4 monomer complex in a 150 mM NaCl saline box of 80×80×109.7Å 3 without the lipid bilayer. Again, this reduction in system size does not introduce additional errors because all the molecules reduced are beyond the cut-off distance from the ligand; EDO/PDO is not charged; and the alpha carbons on the central parts of the helices are fixed as in the case of the full tetramermembrane system.
Computing Binding Affinities with hSMD Method
The formulas and validation of hSMD method can be found in Refs. [39] [40] . In this study, we only employ the case of one pulling center, n= 1, and briefly outline the hSMD formulation below. Following the standard literature [56, 57] , the binding affinity at one binding site is In the case of PDO, r 1 is chosen as the center of mass of the entire ligand.) The integral has the units of Å 3 that renders the right hand side dimensionless as it should be. is computed from SMD runs following the multi-sectional scheme described in Ref. [58] . The partial partition 0 Z is computed in ways according to the nature of the ligand's fluctuations at the binding site (described in the subsequent two subsections).
When the Ligand Fluctuations Can Be Approximated as 3D Gaussian, as in the case of AZM, all we have to do is to evaluate the fluctuations around the binding site. In this case, we have the dissociation constant, within the Gaussian approximation of the fluctuations at the binding site,
Here the dimensionless quantity 1 B k T ∆ gives a measure of how far 10 10 10 (x , y , z ) = 10 r , the initial state chosen for SMD, is from the PMF minimum 1min r that is equal to the average vector ( )
The brackets stand for statistical average and the superscript T transposes a single-row matrix into a single-column matrix. Det represents the determinant. 
which can be accurately evaluated by running equilibrium MD in the bound state of the ligand-protein complex. When the ligand fluctuations cannot be approximated as 3D gaussian, as in the case of EDO/PDO, however, one would have to evaluate the partial partition 0 Z differently. Considering integration on the xy-plane (parallel to the membrane and perpendicular to the AQP4 channel axis) separately from the integration along the channel axis (z-axis), we can factor the partial partition into two ratios: . (10) The first ratio can be well approximated as Gaussian when the SMD initial state 
The second ratio can be expressed integration along the z-axis ( 10 z is constant in the integral) and the integrand is simply related to the 1D PMF difference, is computed by conducting SMD runs in which only the z-coordinate is steered while the xand y-coordinates are free to fluctuate inside the channel [59] . The fluctuations on the xy-plane 1 1 10 (x , y , z ) are measured to compute the deviation of the initial state from the average state on the xy-plane ( ) ( ) 
Slightly different from the case of AZM, the brackets in this case represent statistical average on the xy-plane.
